Free tool
FAERS Monitor: Novolog Penfill
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020986 or its brand name (Novolog Penfill, Insulin Aspart Recombinant). Reports on generic versions are filed under their own applications.
Reports
61,414
Serious
38,468
63% of reports
Hospitalization
20,463
Death reported
4,442
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased9,657
- nausea3,691
- drug ineffective3,180
- blood glucose decreased3,122
- fatigue2,601
- diarrhoea2,554
- dyspnoea2,528
- vomiting2,383
- off label use2,041
- dizziness1,927
- fall1,784
- headache1,776
- death1,755
- weight decreased1,743
- pain1,737
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 192 |
| 2005 | 397 |
| 2006 | 808 |
| 2007 | 915 |
| 2008 | 816 |
| 2009 | 1,421 |
| 2010 | 1,195 |
| 2011 | 1,413 |
| 2012 | 1,495 |
| 2013 | 1,789 |
| 2014 | 2,349 |
| 2015 | 4,610 |
| 2016 | 4,867 |
| 2017 | 4,720 |
| 2018 | 5,250 |
| 2019 | 4,672 |
| 2020 | 4,356 |
| 2021 | 3,829 |
| 2022 | 3,401 |
| 2023 | 2,956 |
| 2024 | 3,264 |
| 2025 | 4,053 |
| 2026 | 2,646 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,992,745 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 3,122 | 23.7 | 22.9 | 63,720 |
| blood glucose increasedSignal | 9,657 | 18.4 | 18.1 | 152,544 |
| weight decreasedSignal | 1,743 | 2.1 | 2.0 | 1,072 |
| fall | 1,784 | 1.8 | 1.8 | 691 |
| vomiting | 2,383 | 1.7 | 1.7 | 762 |
| nausea | 3,691 | 1.6 | 1.6 | 858 |
| dyspnoea | 2,528 | 1.5 | 1.5 | 477 |
| diarrhoea | 2,554 | 1.4 | 1.3 | 245 |
| dizziness | 1,927 | 1.3 | 1.3 | 156 |
| fatigue | 2,601 | 1.1 | 1.1 | 49 |
| headache | 1,776 | 1.0 | 0.9 | 2 |
| pain | 1,737 | 1.0 | 0.9 | 2 |
| drug ineffective | 3,180 | 0.8 | 0.8 | 124 |
| off label use | 2,041 | 0.8 | 0.8 | 109 |
| death | 1,755 | 0.7 | 0.7 | 240 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.